Treats spasticity. ANDA 76282, held by Aurobindo Pharma USA. Tizanidine Hydrochloride.
As of Nov 21, 2026, ANDA 76282 (Tizanidine Hydrochloride), held by Aurobindo Pharma USA, was first approved by FDA on Dec 16, 2003, with 2 approved supplements and 0 published complete response letters.
Tizanidine tablets are indicated for the treatment of spasticity in adults. Tizanidine tablets are a central alpha-2-adrenergic agonist indicated for the treatment of spasticity.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 16, 2003 | Original application | Approved | None posted |
| Tizanidine HydrochlorideEQ 2MG BASE · tablet;oral | Tizanidine Hydrochloride | Rx |
| Tizanidine HydrochlorideEQ 4MG BASE · tablet;oral | Tizanidine Hydrochloride | Rx |
| Oct 22, 2020 | Supplement 4Labeling · Standard review | Approved | None posted |
| Apr 28, 2008 | Supplement 2Labeling | Approved | None posted |
| Dec 16, 2003 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters